
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/122915/publications.pdf Version: 2024-02-01



IAKOR RECLIN

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Ov	verlock 10	Tf 50742 T 1,430742 T
2	Long-Lived <i>C. elegans daf-2</i> Mutants Are Resistant to Bacterial Pathogens. Science, 2003, 300, 1921-1921.	12.6	528
3	Caenorhabditis elegans as a Model Host for Staphylococcus aureus Pathogenesis. Infection and Immunity, 2003, 71, 2208-2217.	2.2	290
4	IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3526-3531.	7.1	273
5	The worm has turned – microbial virulence modeled in Caenorhabditis elegans. Trends in Microbiology, 2005, 13, 119-127.	7.7	266
6	High Fat Diets Induce Colonic Epithelial Cell Stress and Inflammation that is Reversed by IL-22. Scientific Reports, 2016, 6, 28990.	3.3	243
7	Crystal structure of an Xrcc4-DNA ligase IV complex. Nature Structural Biology, 2001, 8, 1015-1019.	9.7	229
8	Review article: consensus statements on therapeutic drug monitoring of antiâ€ŧumour necrosis factor therapy in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2017, 46, 1037-1053.	3.7	225
9	The LRR and RING Domain Protein LRSAM1 Is an E3 Ligase Crucial for Ubiquitin-Dependent Autophagy of Intracellular Salmonella Typhimurium. Cell Host and Microbe, 2012, 12, 778-790.	11.0	202
10	Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis. PLoS Genetics, 2013, 9, e1003723.	3.5	185
11	MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota. Immunity, 2019, 51, 885-898.e7.	14.3	164
12	Staphylococcal Biofilm Exopolysaccharide Protects against Caenorhabditis elegans Immune Defenses. PLoS Pathogens, 2007, 3, e57.	4.7	146
13	Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut, 2018, 67, 973-985.	12.1	116
14	Genetic Coding Variant in GPR65 Alters Lysosomal pH and Links Lysosomal Dysfunction with Colitis Risk. Immunity, 2016, 44, 1392-1405.	14.3	106
15	Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet, The, 2022, 399, 2200-2211.	13.7	94
16	DAF-16-Dependent Suppression of Immunity During Reproduction in <i>Caenorhabditis elegans</i> . Genetics, 2008, 178, 903-918.	2.9	90
17	Substrate-Based Cyclic Peptidomimetics of Phe-Ile-Val That Inhibit HIV-1 Protease Using a Novel Enzyme-Binding Mode. Journal of the American Chemical Society, 1996, 118, 3375-3379.	13.7	77
18	Staphylococcus aureus Virulence Factors Identified by Using a High-Throughput Caenorhabditis elegans-Killing Model. Infection and Immunity, 2005, 73, 872-877.	2.2	77

#	Article	IF	CITATIONS
19	Colonic microbiota can promote rapid local improvement of murine colitis by thioguanine independently of T lymphocytes and host metabolism. Gut, 2017, 66, 59-69.	12.1	65
20	Getting the Adrenaline Going. Structure, 2001, 9, 977-985.	3.3	60
21	Molecular Recognition of Macrocyclic Peptidomimetic Inhibitors by HIV-1 Proteaseâ€,‡. Biochemistry, 1999, 38, 7978-7988.	2.5	56
22	The gut bacterium and pathobiont Bacteroides vulgatus activates NF-κB in a human gut epithelial cell line in a strain and growth phase dependent manner. Anaerobe, 2017, 47, 209-217.	2.1	55
23	Australian consensus statements for the regulation, production and use of faecal microbiota transplantation in clinical practice. Gut, 2020, 69, 801-810.	12.1	52
24	A systematic review and meta-analysis of mindfulness based interventions and yoga in inflammatory bowel disease. Journal of Psychosomatic Research, 2019, 116, 44-53.	2.6	51
25	Cancer therapeutics with epigallocatechin-3-gallate encapsulated in biopolymeric nanoparticles. International Journal of Pharmaceutics, 2017, 518, 220-227.	5.2	46
26	Integrated Genomics of Crohn's Disease Risk Variant Identifies a Role for CLEC12A in Antibacterial Autophagy. Cell Reports, 2015, 11, 1905-1918.	6.4	45
27	The role of barrier function, autophagy, and cytokines in maintaining intestinal homeostasis. Seminars in Cell and Developmental Biology, 2017, 61, 51-59.	5.0	45
28	Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease: Systematic Review and Expert Consensus Statement. Journal of Crohn's and Colitis, 2022, 16, 554-580.	1.3	43
29	Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease. Alimentary Pharmacology and Therapeutics, 2021, 53, 873-886.	3.7	43
30	Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Alimentary Pharmacology and Therapeutics, 2020, 52, 1551-1562.	3.7	38
31	Monitoring Inflammatory Bowel Disease in Pregnancy Using Gastrointestinal Ultrasonography. Journal of Crohn's and Colitis, 2020, 14, 1405-1412.	1.3	35
32	The role of <scp>IL</scp> â€22 in the resolution of sterile and nonsterile inflammation. Clinical and Translational Immunology, 2018, 7, e1017.	3.8	31
33	pH – Responsive colloidal carriers assembled from β-lactoglobulin and Epsilon poly-L-lysine for oral drug delivery. Journal of Colloid and Interface Science, 2021, 589, 45-55.	9.4	31
34	MUC13 promotes the development of colitis-associated colorectal tumors via β-catenin activity. Oncogene, 2019, 38, 7294-7310.	5.9	28
35	Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on diseaseâ€related knowledge. JCH Open, 2020, 4, 267-272.	1.6	28
36	Thiopurine Therapy in Inflammatory Bowel Diseases: Making New Friends Should Not Mean Losing Old Ones. Gastroenterology, 2019, 156, 11-14.	1.3	27

#	Article	IF	CITATIONS
37	Oneâ€Pot Synthesis of pHâ€Responsive Eudragitâ€Mesoporous Silica Nanocomposites Enable Colonic Delivery of Glucocorticoids for the Treatment of Inflammatory Bowel Disease. Advanced Therapeutics, 2021, 4, 2000165.	3.2	26
38	Malnutrition and quality of life among adult inflammatory bowel disease patients. JGH Open, 2020, 4, 454-460.	1.6	23
39	Secreted NF-κB suppressive microbial metabolites modulate gut inflammation. Cell Reports, 2022, 39, 110646.	6.4	22
40	IFN-λ therapy prevents severe gastrointestinal graft-versus-host disease. Blood, 2021, 138, 722-737.	1.4	21
41	Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas. Clinical Gastroenterology and Hepatology, 2022, 20, 1306-1314.	4.4	19
42	Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and metaâ€analysis. Medical Journal of Australia, 2019, 211, 461-467.	1.7	18
43	Distinct Tissue-Specific Roles for the Disease-Associated Autophagy Genes ATG16L2 and ATG16L1. Journal of Immunology, 2019, 203, 1820-1829.	0.8	18
44	Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. Alimentary Pharmacology and Therapeutics, 2022, 55, 700-704.	3.7	17
45	Towards an integrated understanding of the therapeutic utility of exclusive enteral nutrition in the treatment of Crohn's disease. Food and Function, 2016, 7, 1741-1751.	4.6	16
46	Clinical decision support improves quality of care in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2019, 49, 1040-1051.	3.7	16
47	Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World Journal of Gastroenterology, 2020, 26, 4428-4441.	3.3	16
48	Enterococcus faecalis AHG0090 is a Genetically Tractable Bacterium and Produces a Secreted Peptidic Bioactive that Suppresses Nuclear Factor Kappa B Activation in Human Gut Epithelial Cells. Frontiers in Immunology, 2018, 9, 790.	4.8	15
49	Letter: vedolizumab drug concentrations in neonates following intrauterine exposure. Alimentary Pharmacology and Therapeutics, 2018, 48, 1328-1330.	3.7	14
50	Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. Medical Journal of Australia, 2021, 214, 128-133.	1.7	14
51	Mindfulness based cognitive therapy for youth with inflammatory bowel disease and depression - Findings from a pilot randomised controlled trial. Journal of Psychosomatic Research, 2021, 149, 110594.	2.6	14
52	lgM and IgA augmented autoantibody signatures improve earlyâ€stage detection of colorectal cancer prior to nodal and distant spread. Clinical and Translational Immunology, 2021, 10, e1330.	3.8	13
53	Practical management of inflammatory bowel disease patients during the COVID â€19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty. Internal Medicine Journal, 2020, 50, 798-804.	0.8	12
54	A Nucleotide Analog Prevents Colitis-Associated Cancer via Beta-Catenin Independently of Inflammation and Autophagy. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 33-53.	4.5	12

#	Article	IF	CITATIONS
55	Colonic thioguanine pro-drug: Investigation of microbiome and novel host metabolism. Gut Microbes, 2018, 9, 175-178.	9.8	11
56	Crohn's Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2020, 55, 1419-1426.	1.5	11
57	Gut microbiota shape the inflammatory response in mice with an epithelial defect. Gut Microbes, 2021, 13, 1-18.	9.8	11
58	Autophagy at the crossroads of metabolism and cellular defense. Current Opinion in Gastroenterology, 2013, 29, 588-596.	2.3	10
59	Psychosocial burden of inflammatory bowel disease in adolescents and young adults. Internal Medicine Journal, 2021, 51, 2027-2033.	0.8	10
60	Protocol for a pilot randomised controlled trial of mindfulness-based cognitive therapy in youth with inflammatory bowel disease and depression. BMJ Open, 2019, 9, e025568.	1.9	9
61	Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterology, 2022, 9, e000853.	2.7	9
62	Crystallization and preliminary X-ray analysis of thiaminase I from Bacillus thiaminolyticus: space group change upon freezing of crystals. Acta Crystallographica Section D: Biological Crystallography, 1998, 54, 448-450.	2.5	8
63	Mindfulness-based cognitive therapy experiences in youth with inflammatory bowel disease and depression: findings from a mixed methods qualitative study. BMJ Open, 2020, 10, e041140.	1.9	7
64	SARS oVâ€2 vaccination in patients with inflammatory bowel disease. GastroHep, 2021, 3, 212-228.	0.6	7
65	Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages. PLoS Pathogens, 2022, 18, e1010166.	4.7	7
66	Crystallization of PNMT, the adrenaline-synthesizing enzyme, is critically dependent on a high protein concentration. Acta Crystallographica Section D: Biological Crystallography, 2002, 58, 314-315.	2.5	6
67	Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scandinavian Journal of Gastroenterology, 2021, , 1-8.	1.5	6
68	Expression of CD49f defines subsets of human regulatory TÂcells with divergent transcriptional landscape and function that correlate with ulcerative colitis disease activity. Clinical and Translational Immunology, 2021, 10, e1334.	3.8	5
69	Mindfulness-Based Cognitive Therapy Experiences in Youth With Inflammatory Bowel Disease and Depression: Protocol for a Mixed Methods Qualitative Study. JMIR Research Protocols, 2019, 8, e14432.	1.0	5
70	Enteroliths in a Kock continent ileostomy: case report and review of the literature. Endoscopy, 2015, 47, E200-E201.	1.8	4
71	Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. BMJ Open, 2021, 11, e043921.	1.9	4
72	Facile synthesis of dendrimer like mesoporous silica nanoparticles to enhance targeted delivery of interleukin-22. Biomaterials Science, 2021, 9, 7402-7411.	5.4	4

#	Article	IF	CITATIONS
73	Inflammatory bowel disease in the clinic: Escalation and deâ€escalation of therapy: A longitudinal caseâ€based discussion. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 12-13.	2.8	2
74	Interleukinâ€⊋2: friend or foe?. Immunology and Cell Biology, 2019, 97, 355-357.	2.3	2
75	Adhesion to Eâ€selectin primes macrophages for activation through AKT and mTOR. Immunology and Cell Biology, 2021, 99, 622-639.	2.3	2
76	Successful Manipulation of the Gut Microbiome to Treat Spontaneous and Induced Murine Models of Colitis. , 2022, 1, 359-374.		1
77	The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis. Intestinal Research, 2023, 21, 161-167.	2.6	1
78	ATG16L1 T300A Dependent Differential Gene Expression Identifies Genes Required for Anti-Bacterial Autophagy. Inflammatory Bowel Diseases, 2012, 18, S103.	1.9	0
79	Selectively targeting the gut in inflammatory bowel disease: Session four summary. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 25-25.	2.8	0
80	Positioning biologics—A caseâ€based discussion: Ustekinumab. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 16-17.	2.8	0
81	Personalizing inflammatory bowel disease treatment symposium: Foreward. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 3-3.	2.8	0
82	Predictors in inflammatory bowel disease: Looking into the magic ball: Session one summary. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 4-4.	2.8	0
83	The future of faecal microbiota transplantation in gastrointestinal illness. Microbiology Australia, 2020, 41, 70.	0.4	0
84	Aeromedical retrievals for gastrointestinal disorders in rural and remote Australia: the need for improved access to specialist advice. Internal Medicine Journal, 2020, 50, 619-623.	0.8	0
85	Interferon Lambda Protects Gastrointestinal Stem Cells from Acute Gvhd. Transplantation and Cellular Therapy, 2021, 27, S78.	1.2	0
86	So many therapies—So little data: How to choose? Session two summary. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 14-15.	2.8	0